# Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months

Study · id `cardio:ct-nct06723717` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06723717](<https://clinicaltrials.gov/study/NCT06723717>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06723717

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 304 participants.

## Technical summary

Registry record NCT06723717. Randomized; single masking; primary purpose prevention. Start 2025-09-26 (actual); primary completion 2028-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 304 participants (planned count; ClinicalTrials.gov record NCT06723717, source copy `cardio:ctgov-nct06723717-2026-05-08`, retrieved 2026-10-31)
- Started: 2025-09-26 (actual) (ClinicalTrials.gov record NCT06723717, source copy `cardio:ctgov-nct06723717-2026-05-08`, retrieved 2026-10-31)
- Primary completion: 2028-03 (anticipated) (ClinicalTrials.gov record NCT06723717, source copy `cardio:ctgov-nct06723717-2026-05-08`, retrieved 2026-10-31)
- Completion: 2028-09 (anticipated) (ClinicalTrials.gov record NCT06723717, source copy `cardio:ctgov-nct06723717-2026-05-08`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT06723717, source copy `cardio:ctgov-nct06723717-2026-05-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06723717-2026-05-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months
- Acronym: RESET
- Condition: Ruptured Aneurysm of Intracranial Artery
- Condition: SAH (Subarachnoid Hemorrhage)
- Condition: Delayed Cerebral Ischemia
- Intervention (Drug): Daily infusion of dornase alfa
- Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
- Lead sponsor class: NETWORK

## Connected pages

- Registry condition terms include this condition: Subarachnoid hemorrhage (`cardio:subarachnoid-hemorrhage`)

## Provenance

Content hash: 923001255526b7e57d30e326eb97f22f080be315fa93b2ab6870fce425f5fcca
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
